Abstract:Background One of the major challenges in the management of rheumatoid arthritis (RA) is to determine individual treatment and predict the prognosis. On a group level, high disease activity and antibodies specific for citrulline (ACPA) and immunoglobulins (RF) are factors associated with poor prognosis. New alternative biomarkers, which could provide more specific information, are antibodies to disease-related targets in the joints [1] Objectives To identify circulating autoantibodies to joint-related proteins (hereafter named JointIDs) that predict disease outcome in patients with new onset RA. Methods Sera at diagnosis from BARFOT and TIRA-2 cohorts (n=1986) with new onset RA patients were screened with a bead-based multiplex flow immunoassay to detect IgG autoantibodies against 47 peptides derived from joint proteins (JointIDs) (Lönnblom, under review 2023). Disease outcomes included Boolean remission at 6 and 12 months, swollen joint count (SJC) and radiological progression at 12 months (>8% affected feet joints and >3% affected hand joints) in patients who were without joint damage at inclusion. Multivariate logistic regression and zero-inflated negative binomial models adjusted for clinical factors (age, gender, ACPA, RF, changes in medication at 3 and 6 months) were used to identify JointIDs with the strongest potential to predict prognosis. Results Six JointIDs were identified as predictors for these disease outcomes in multivariate analyses. Presence of JointID178 predicted an average decrease in SJC at 6 months with 41% and with 33% at 12 months. Presence of at least 2 of the following factors: JointID178 positive and JointID199 negative at inclusion in combination with male sex identified approx. 40% of the patients in Boolean remission at 6 months with approx. 75% specificity (Table 1). A similar test performance was obtained even for Disease Activity Score 28 remission. The sensitivity and specificity for being in Boolean remission at 12 months if the patients were male, negative for JointID199 and in Boolean remission at 6 months was 13% (CI 9%;16%) and 99% (CI 99%;100%), respectively. RF and ACPA did not predict remission but were the strongest predictors of joint destruction at 12 months although with low specificity (58%). Addition of JointID166 significantly increased the specificity at the expense of sensitivity. Conclusion Autoantibodies to joint-related proteins at RA diagnosis can predict remission with a high specificity at 6 and 12 months. This knowledge is of clinical importance as patients positive or negative for these JointIDs in combination with clinical factors may potentially guide future treatment choices. Reference [1]Holmdahl R, Malmstrom V, Burkhardt H. Autoimmune priming, tissue attack and chronic inflammation - the three stages of rheumatoid arthritis. Eur J Immunol 2014; 44(6): 1593-9. Acknowledgements: NIL. Disclosure of Interests Monica Leu Agelii: None declared, Outi Sareila Employee of: OS is an employee of Vacara AB, Erik Lönnblom Consultant of: EL is a consultant for Vacara AB, Kristina Forslind: None declared, Ingiäld Hafström: None declared, Maria Andersson: None declared, Alf Kastbom: None declared, Christopher Sjowall: None declared, Lennart T.H. Jacobsson Speakers bureau: Novartis, Eli-Lily and Janssen, Consultant of: Participated in Advisory Boards for Pfizer, Novartis, Eli-Lily and Janssen., Jan Kihlberg: None declared, Rikard Holmdahl Consultant of: Consulting fees from Regor, Lipum AB and Cyxone AB, Inger Gjertsson: None declared.

Joint Hypermobility, Autonomic Dysfunction, Gastrointestinal Dysfunction and Autoimmune markers (JAG-A): Clinical Associations and Response to Intravenous Immunoglobulin Therapy

S2276 Response of Autoimmune Gastroparesis to Immunomodulation

Evaluating Autoimmune Markers in Relation to Gastrointestinal Measures in Patients With Symptoms of Gastroparesis

Elevated total serum IgM predicts the presence of antiphospholipid antibodies in dysautonomia patients

Transient positive antimitochondrial M2 in sera of patients with connective tissue diseases after intravenous immunoglobulin infusions

Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy

INTRAVENOUS IMMUNOGLOBULINS LEAD TO FUNCTIONAL VASCULAR AMELIORATION IN LONG-COVID

The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies

Clinical Immunological Characteristics of Anti-Interferon-γ Autoantibodies Syndrome: A 3 Year Prospective Cohort Study

A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response

Association of Autoantibody Specificity and Response to Intravenous Immunoglobulin G Therapy in Immune Thrombocytopenia: A Multicenter Cohort Study

Efficacy assessment of intravenous immunoglobulin for gastrointestinal involvement in systemic sclerosis using UCLA SCTC GIT: Case-based review

IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety

Hemoperfusion and Intravenous Immunoglobulins for Refractory Gastrointestinal Involvement in Pediatric Henoch-Schönlein Purpura: a Single-Center Retrospective Cohort Study.

Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy

P135 Association of Serum Anti-Muscarinic 3 Antibodies with Gastrointestinal Disease in Systemic Sclerosis

A case of erythromelalgia with gastrointestinal dysautonomia treated with immunoglobulin: A case report

A double‐blind placebo‐controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS‐HDS and FGFR‐3 autoantibodies

OP0123 AUTOANTIBODIES TO JOINT-RELATED PROTEINS PREDICT REMISSION IN NEW ONSET RA WITH HIGH SPECIFICITY

Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity

Benefits of Early vs Late Initiation of IVIG in the Treatment of Anti‐HMGCR Immune‐Mediated Necrotizing Myopathy